… In brief, arteries (diameter: 5–10 mm) were kept in Dulbecco's modified Eagle medium (DMEM)
at 4C before their intimal cell layer and residual adventitial tissue were stripped off using …

Objective To describe the response to first‐line immunosuppressive therapy with or without
pulmonary vasodilators in pulmonary arterial hypertension (PAH) associated with systemic …

… C, D. No difference was observed in mean pulmonary arterial pressure (mPAP) (panel C),
or cardiac index (panel D). E. Pulmonary capillary wedge pressure was in similar proportions …

… The presence of cirrhosis, cirrhosis with B or C Child Pugh scores, high right atrial pressure,
… Only the absence of cirrhosis, Child-Pugh scores B and C, and cardiac index were identified …

Objectives. Rituximab has been shown to induce remission of ANCA-associated vasculitides
(AAVs). Our study was undertaken to describe AAV clinical responses to rituximab used for …

… Drs LePavec, Lrillon, Tcherakian, and Feuillet have reported that no potential conflicts of
interest exist with any companies/organizations whose products or services may be discussed …

Background In idiopathic pulmonary fibrosis (IPF) the distribution and spatial-temporal
progression of fibrotic changes may be influenced by general or locoregional conditions. From …

Objective. Data on long-term efficacy of bosentan, an oral dual ET receptor antagonist, in
SSc-associated pulmonary arterial hypertension (SSc-PAH) are lacking. We aimed to describe …

Disclosures: Dr. Chen reported grants from Bristol-Myers Squibb during the conduct of the
study. Dr. Rosenfeld reported personal fees from Baylor Genetics Laboratories outside the …

Pulmonary arterial hypertension (PAH) is associated with dysregulated bone morphogenetic
protein receptor (BMPR)-II signaling and pulmonary vascular inflammation. We evaluated …